Key Details
Price
$3.80Annual Revenue
$572.42 MAnnual EPS
-$4.10Annual ROE
-33.47%Beta
2.13Events Calendar
Next earnings date:
Dec 11, 2024Recent quarterly earnings:
Aug 08, 2024Recent annual earnings:
Dec 11, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the “Second Lien Notes”), and warrants to purchase common shares, to certain investors in a private offering.
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates:
Company reaffirms commitment to maintaining appropriate standards of animal welfare Company reaffirms commitment to maintaining appropriate standards of animal welfare
WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference.
Inotiv stock is experiencing a decline on Tuesday following the release of preliminary results for Q1 2024 by the drug discovery and development services company. The company has reported that its revenue for the six months ending on March 31, 2024 is expected to be $254.5 million.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Inotiv, Inc. (NOTV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
In the stock market, identifying the next big opportunity is like observing a celestial phenomenon. Today, through the cosmos of investment, three shining stars are identified for their potential for astronomical valuation possibilities.
FAQ
- What is the primary business of Inotiv?
- What is the ticker symbol for Inotiv?
- Does Inotiv pay dividends?
- What sector is Inotiv in?
- What industry is Inotiv in?
- What country is Inotiv based in?
- When did Inotiv go public?
- Is Inotiv in the S&P 500?
- Is Inotiv in the NASDAQ 100?
- Is Inotiv in the Dow Jones?
- When was Inotiv's last earnings report?
- When does Inotiv report earnings?
- Should I buy Inotiv stock now?